Hepatitis means inflammation of the liver. The liver is a vital organ that processes nutrients, filters the blood, and fights infections. When the liver is inflamed or damaged, its function can be affected, says the U.S. CDC.
The CDC's Division of Viral Hepatitis Strategic Plan outlines goals, strategic approaches, objectives, and outcome measures for making measurable progress in reducing new viral hepatitis infections and viral hepatitis-associated illnesses, deaths, and disparities in the USA during the next five years.
Hepatitis Vaccines - U.S. FDA Authorized
Engerix-B is a Hepatitis B Vaccine that is a noninfectious recombinant DNA hepatitis B vaccine.
Havrix Hepatitis A Vaccine is indicated for active immunization against disease caused by the hepatitis A virus.
Hecolin is a recombinant vaccine that contains the hepatitis E virus (HEV)-like particles prepared using a recombinant Escherichia coli expression system.
Heplisav-B combines hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR), 9 agonists, to enhance the immune response.
Recombivax HB is a recombinant vaccine that contains synthetic Hepatitis B surface antigen (HBsAg).
Twinrix Hepatitis Vaccine is indicated for active immunization against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus.
Hepatitis Vaccine Candidates
HBAI20 vaccine candidate consists of a standard HBV vaccine to which the AI20 adjuvant is added.
Sci-B-Vac is a third-generation hepatitis B trivalent vaccine that mimics all three surface antigens, pre-S1, pre-S2, and S, of the hepatitis B virus. Approved in Israel.
VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.
VTP-300 vaccine candidate utilize Vaccitech’s ChAdOx1-MVA prime-boost combination to elicit an immune response against HBV. The HBV DNA sequence in the viral vectors is derived from a genotype C sequence, which is the most common genotype circulating worldwide.
Hepatitis Vaccine News
May 11, 2021 - The Lancet published a study: Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomized, double-blind, phase 3 trial. Interpretation - The safety and efficacy of the tri-antigenic hepatitis B vaccine shows its usefulness for the prevention of HBV infection in adults, including those with stable and controlled chronic conditions. Funding - VBI Vaccines.
April 21, 2021 - Brii Biosciences, Vir Biotechnology, Inc., and VBI Vaccines Inc. announced that the first patient had been dosed in Phase 2 clinical trial evaluating BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid-targeting hepatitis B virus (HBV), in combination with BRII-179 (VBI-2601), an investigational HBV immunotherapeutic, for the treatment of chronic HBV infection. This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.
April 12, 2021 - VBI Vaccines Inc. announced data and next steps from the high-dose cohort of its Phase 1b/2a clinical study of VBI-2601 (BRII-179), the company’s hepatitis B immunotherapeutic candidate, in chronically infected hepatitis B patients. VBI-2601 (BRII-179) is being developed in collaboration with Brii Biosciences as part of a potential functional cure for chronic hepatitis B virus infection.
February 24, 2021 - San Diego-based VLP BioTech, Inc. announced the development of a more practical vaccine-based viral entry inhibitor to block HBV/HDV liver invasion. The company is seeking potential partners or licensees interested in this technology or combination therapies' clinical development.
February 19, 2021 - Dynavax Technologies Corporation announced that the European Commission had granted Marketing Authorization for HEPLISAV B (Hepatitis B Vaccine (Recombinant), Adjuvanted) for the active immunization against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
February 2, 2021 - VBI Vaccines Inc. announced that the U.S. Food and Drug Administration had accepted its filing of the Biologics License Application for the Company’s 3-antigen prophylactic hepatitis B vaccine candidate for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.
February 1, 2021 - Vaccitech Ltd. announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose anti-PD-1 antibody in patients with chronic hepatitis B infection. The study plans to enroll 64 patients in South Korea, Taiwan, and the UK.
January 25, 2021 - Atlanta-based Antios Therapeutics, Inc. announced that it had completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with chronic hepatitis B virus infection. ATI-2173 is a novel, orally-administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) molecule designed to deliver the 5’-monophosphate of clevudine to the liver. This L-nucleoside’s active 5’-triphosphate has unique antiviral properties as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the active site of HBV polymerase resulting in potent HBV antiviral activity and extended off-treatment suppression of HBV DNA. ATI-2173 targets the liver, delivering high levels of the unique 5’- triphosphate while limiting systemic exposure to the parent L-nucleoside. ATI-2173 has the potential to become an integral part of a curative combination regimen for chronic hepatitis B.
January 15, 2021 - VBI Vaccines Inc. announced that results from a Phase 4 study of VBI’s prophylactic 3-antigen Hepatitis B virus (HBV) vaccine in younger adults were published in Vaccine, a journal publication from Elsevier. The study was designed to evaluate VBI’s 3-antigen HBV vaccine's immunogenicity in support of that batch's qualification as a new reference standard for vaccine release to the Israeli market, where VBI’s vaccine is available as Sci-B-Vac®.
January 12, 2021 - Gilead Sciences and Vir Biotechnology, Inc. announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies to develop a functional cure for the chronic hepatitis B virus. Anuj Gaggar, VP, Clinical Research, Virology at Gilead, stated, “We believe that selgantolimod and VIR-2218 have the potential to be best-in-class therapeutics and could provide a compelling new combination approach to a functional cure for HBV.”
January 7, 2021 - The U.S. Department of Health and Human Services released a national plan to address the serious, preventable public health threat caused by viral hepatitis in the United States. The Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination 2021–2025 sets national goals, objectives, and strategies to respond to viral hepatitis epidemics. Building on three prior National Viral Hepatitis Action Plans over the last 10 years, and the Viral Hepatitis National Strategic Plan is the first to eliminate viral hepatitis as a public health threat in the United States 2030.
December 30, 2020 - A Maryland-based biopharmaceutical company announced that it had enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a novel peptide-based immunotherapeutic under development to treat chronic hepatitis B.
December 15, 2020 - The U.S. Preventive Services Task Force published a final recommendation statement on screening for hepatitis B virus infection in adolescents and adults. Based on its review of the evidence, the Task Force recommends that clinicians screen teens and adults at increased risk of hepatitis B infection to help prevent serious health problems. “Screening teens and adults who are at increased risk for hepatitis B infection can help detect the virus and enable treatment to prevent serious health effects,” says Task Force member Chyke Doubeni, M.D., M.P.H. “Evidence consistently shows that screening and early treatment leads to better health outcomes.”
July 18, 2020 - The USA has been experiencing person-to-person outbreaks of hepatitis A in unprecedented numbers during the vaccine era. As of May 2020, 33 states had reported hepatitis A outbreaks involving approximately 32,500 cases reported by the Centers for Disease Control and Prevention.
February 3, 2020 - The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices published the revised Recommended Adult Immunization Schedule for 2020 in the Annals of Internal Medicine.
Note: This content has been reviewed by healthcare professions, such as Dr. Robert Carlson.